Table 1 Comparison of Baseline Characteristics of Patients with the NCPF-Enriched and NCPF-Low Cohorts.
Parameter | NCPF-Enriched | NCPF-Low | p-value |
|---|---|---|---|
Age at Diagnosis, median (years) | 67.5 | 67.2 | 0.88 |
Sex, % males | 61.2 | 61.9 | 0.92 |
BMPC infiltrate, median (%) | 20 | 50 | <0.0001 |
≥50% BMPC, % | 16.9 | 55.2 | <0.0001 |
Elevated S-phase fraction (≥2%), % | 16.9 | 15.6 | 0.68 |
Cytogenetics | |||
Del(17p), % | 15.2 | 12.6 | 0.44 |
1q duplication, % | 25.6 | 31.4 | 0.2 |
t(4;14), % | 11.5 | 9.1 | 0.4 |
t(11;14), % | 14.3 | 24.3 | 0.02 |
t(14;16)/t(14;20), % | 2.7 | 5.3 | 0.34 |
Hyperdiploid, % | 71.1 | 58.8 | 0.025 |
≥2 HRCA | 11.8 | 13.2 | 0.76 |
IMS/IMWG High-risk, % | 25.2 | 25.5 | 0.94 |
Treatment Data | |||
Induction, % | 0.09 | ||
Triplet | 79.8 | 72 | |
Quadruplet | 7 | 14.2 | |
Doublet | 13.2 | 13.8 | |
ASCT, % | 45.3 | 40.5 | 0.35 |
Maintenance Utilized, % | 93.9 | 89.3 | 0.2 |
Maintenance Utilized, % | 0.28 | ||
IMiD | 58 | 50.2 | |
PI | 17.2 | 14.7 | |
IMiD + PI | 16.1 | 21 | |
Daratumumab+IMiD | 8.6 | 14 | |
